FDA approval of benzgalantamine exposes flaws in the 505(b)(2) pathway for innovations on existing drugs.

BMJ evidence-based medicine

Reddy NK, Steinman MA, Ross JS, Widera E, Zeldes N, Steinbrook R, Ramachandran R. FDA approval of benzgalantamine exposes flaws in the 505(b)(2) pathway for innovations on existing drugs. BMJ Evid Based Med. 2026 Mar 02.

2026

https://researcherprofiles.org/profile/755922485

41771551

Reddy NK, Steinman MA, Ross JS, Widera E, Zeldes N, Steinbrook R, Ramachandran R